

Bone Marrow-Specific Knock-In of a Non-Activatable $Ikk\alpha$ Kinase Mutant Influences Haematopoiesis but Not Atherosclerosis in *Apoe*-Deficient Mice

Pathricia V. Tilstam¹, Marion J. Gijbels^{2,3}, Mohamed Habbeddine⁴, Céline Cudejko⁴, Yaw Asare^{1,5}, Wendy Theelen¹, Baixue Zhou¹, Yvonne Döring⁶, Maik Drechsler⁶, Lukas Pawig¹, Sakine Simsekylmaz¹, Rory R. Koenen², Menno P. J. de Winther^{2,3}, Toby Lawrence⁴, Jürgen Bernhagen^{5,7}, Alma Zerneck^{8,9,10}, Christian Weber^{2,6,10*}, Heidi Noels^{1*}

1 Institute of Molecular Cardiovascular Research, RWTH Aachen University, Aachen, Germany, **2** Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands, **3** Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, **4** Centre d'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France, **5** Institute of Biochemistry and Molecular Cell Biology, RWTH Aachen University, Aachen, Germany, **6** Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany, **7** August-Lenz-Stiftung, Institute for Cardiovascular Research, Ludwig-Maximilians-University Munich, Munich, Germany, **8** Rudolf Virchow Center and Institute of Clinical Biochemistry and Pathobiochemistry, University of Würzburg, Würzburg, Germany, **9** Department of Vascular Surgery, Klinikum rechts der Isar Technical University Munich, Munich, Germany, **10** German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Munich, Germany

Abstract

Background: The $Ikk\alpha$ kinase, a subunit of the NF- κ B-activating IKK complex, has emerged as an important regulator of inflammatory gene expression. However, the role of $Ikk\alpha$ -mediated phosphorylation in haematopoiesis and atherogenesis remains unexplored. In this study, we investigated the effect of a bone marrow (BM)-specific activation-resistant $Ikk\alpha$ mutant knock-in on haematopoiesis and atherosclerosis in mice.

Methods and Results: Apolipoprotein E (*Apoe*)-deficient mice were transplanted with BM carrying an activation-resistant $Ikk\alpha$ gene ($Ikk\alpha^{AA/AA}Apoe^{-/-}$) or with $Ikk\alpha^{+/+}Apoe^{-/-}$ BM as control and were fed a high-cholesterol diet for 8 or 13 weeks. Interestingly, haematopoietic profiling by flow cytometry revealed a significant decrease in B-cells, regulatory T-cells and effector memory T-cells in $Ikk\alpha^{AA/AA}Apoe^{-/-}$ BM-chimeras, whereas the naive T-cell population was increased. Surprisingly, no differences were observed in the size, stage or cellular composition of atherosclerotic lesions in the aorta and aortic root of $Ikk\alpha^{AA/AA}Apoe^{-/-}$ vs $Ikk\alpha^{+/+}Apoe^{-/-}$ BM-transplanted mice, as shown by histological and immunofluorescent stainings. Necrotic core sizes, apoptosis, and intracellular lipid deposits in aortic root lesions were unaltered. *In vitro*, BM-derived macrophages from $Ikk\alpha^{AA/AA}Apoe^{-/-}$ vs $Ikk\alpha^{+/+}Apoe^{-/-}$ mice did not show significant differences in the uptake of oxidized low-density lipoproteins (oxLDL), and, with the exception of IL-12, the secretion of inflammatory proteins in conditions of Tnf- α or oxLDL stimulation was not significantly altered. Furthermore, serum levels of inflammatory proteins as measured with a cytokine bead array were comparable.

Conclusion: Our data reveal an important and previously unrecognized role of haematopoietic $Ikk\alpha$ kinase activation in the homeostasis of B-cells and regulatory T-cells. However, transplantation of $Ikk\alpha^{AA}$ mutant BM did not affect atherosclerosis in *Apoe*^{-/-} mice. This suggests that the diverse functions of $Ikk\alpha$ in haematopoietic cells may counterbalance each other or may not be strong enough to influence atherogenesis, and reveals that targeting haematopoietic $Ikk\alpha$ kinase activity alone does not represent a therapeutic approach.

Citation: Tilstam PV, Gijbels MJ, Habbeddine M, Cudejko C, Asare Y, et al. (2014) Bone Marrow-Specific Knock-In of a Non-Activatable $Ikk\alpha$ Kinase Mutant Influences Haematopoiesis but Not Atherosclerosis in *Apoe*-Deficient Mice. PLoS ONE 9(2): e87452. doi:10.1371/journal.pone.0087452

Editor: Laurel L. Lenz, National Jewish Health and University of Colorado School of Medicine, United States of America

Received: August 21, 2013; **Accepted:** December 27, 2013; **Published:** February 3, 2014

Copyright: © 2014 Tilstam et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Deutsche Forschungsgemeinschaft (DFG, www.dfg.de) (WE1913/11-2 to CW, KO2948/1-2 to RRK and CW), by the DFG International graduate school grant IRTG1508/1-TP6 (to CW, PVT, JB, MPJdW), by the Alexander von Humboldt Foundation (<http://www.humboldt-foundation.de/web/home.html>) (3.3 BEL/1129548, to HN), by the START Program of the Faculty of Medicine of RWTH Aachen (<http://www.medin.rwth-aachen.de/go/id/tfy>) (to HN and AZ), and by the Netherlands Organization for Health Research and Development (<http://www.zonmw.nl/en/>) (to MPJdW). MPJdW is an established investigator of the Netherlands Heart Foundation (2007T067) (www.hartstichting.nl). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: C.W. is a shareholder of Carolus Therapeutics Inc., a company developing chemokine-based anti-inflammatory strategies. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: kreislaufinstitut@med.uni-muenchen.de (CW); hnoels@ukaachen.de (HN)

† These authors contributed equally to this work.

Introduction

Cardiovascular diseases are the main cause of morbidity and mortality in western societies, with atherosclerosis being the underlying pathology triggering most of the cardio- and cerebrovascular incidents. Atherosclerosis is a chronic inflammatory disease of the vessel wall characterized by the activation of endothelial cells, the subendothelial accumulation of oxidized low-density lipoproteins (oxLDL) and the infiltration of inflammatory cells such as neutrophils, monocytes, dendritic cells (DCs) and lymphocytes [1,2].

A key regulator of inflammation and atherogenesis is the transcription factor nuclear factor κ B (NF- κ B) [3]. The NF- κ B family has 5 members: p65 (RelA), c-Rel, RelB, NF- κ B1 (p105, processed to p50) and NF- κ B2 (p100, processed to p52) [4]. Under resting conditions, canonical NF- κ B dimers (mostly p50/p65) are predominantly found in the cytoplasm bound to the inhibitory of κ B (I κ B)- α protein. Inflammatory signals such as TNF- α and oxLDL activate the I κ B kinase (IKK) complex, which consists of two catalytically active kinases (IKK α /IKK1 and IKK β /IKK2) and one regulatory component (IKK γ /NEMO). The phosphorylation of I κ B- α by IKK β causes its ubiquitination and proteasomal degradation. This releases the NF- κ B dimer, allowing a steady-state localization in the nucleus and the expression of many pro-inflammatory proteins [5]. These pro-inflammatory functions of canonical NF- κ B activation have been linked to atherogenesis *in vivo*, showing reduced lesion formation in hyperlipidaemic *Apolipoprotein E* (*Apoe*)-deficient mice treated with the NF- κ B inhibitor DHMEQ, which prevents the TNF- α -induced nuclear translocation of p65 [6]. Similarly, strongly reduced atherosclerotic plaque formation was observed in *Apoe*^{-/-} mice with an endothelial cell-restricted inhibition of NF- κ B activation through endothelial *Ikk γ* -deficiency or through an endothelial cell-specific expression of a dominant-negative *I κ B- α* transgene [7]. On the other hand, NF- κ B activity in leukocytes also has an important role in the resolution of inflammation through the transcription of anti-inflammatory cytokines such as interleukin (IL)-10 [8] and the suppression of pro-inflammatory IL-1 β secretion [9]. Furthermore, an anti-inflammatory role was described for IKK β by suppression of the classically activated (or M1) macrophage phenotype [10]. These anti-inflammatory properties of IKK/NF- κ B signalling could explain the initially unexpected increase in atherosclerosis in hyperlipidaemic *Ldl receptor* (*Ldlr*)-deficient mice with a myeloid-specific deletion of *Ikk β* , which was linked to a significant reduction of the anti-inflammatory cytokine IL-10 in *Ikk β* ^{-/-} macrophages [11]. Thus, IKK β /NF- κ B signalling plays a complex role in inflammation and atherogenesis by driving both pro- and anti-inflammatory processes, and the outcome of NF- κ B inhibition on atherosclerosis seems strongly dependent on the targeted cell type.

In contrast to IKK β and IKK γ , the role of IKK α in atherogenesis has not been investigated. Although IKK α is not required for canonical I κ B- α phosphorylation and subsequent NF- κ B activation [12,13], the IKK α kinase exerts multiple NF- κ B-dependent and -independent functions that could potentially influence atherogenesis [4,14]. First, IKK α homodimers mediate alternative NF- κ B activation through phosphorylation of NF- κ B p100, triggering p100 processing and the release and nuclear localization of RelB-p52 dimers [4,15]. This pathway, induced by several members of the TNF-superfamily as BAFF and CD40 ligand, plays a central role in B-cell maturation and lymphoid organ formation and may thus implicate IKK α in atherogenesis through the recently appreciated role of B-cells in this pathology [16]. Secondly, nuclear IKK α modulates gene expression through

phosphorylation of histone H3, mediating the expression of a subset of canonical NF- κ B-dependent genes in TNF- α -stimulated mouse embryonic fibroblasts [17,18]. On the other hand, IKK α has also been associated with repression or termination of gene transcription. For example, an anti-inflammatory role has been described for IKK α kinase in macrophages by inducing the phosphorylation, promoter removal and degradation of the canonical NF- κ B isoforms p65 and c-Rel [19]. Furthermore, diverse pro-inflammatory stimuli trigger the IKK α -mediated phosphorylation of the transcriptional repressor PIAS1, which then negatively regulates the expression of a predominantly pro-inflammatory subset of p65- and STAT1-dependent genes [20]. In addition, IKK α -mediated phosphorylation of TAX1BP1 triggers the assembly of the A20 ubiquitin-editing complex, which is an important negative regulator of canonical NF- κ B activation [21]. In conclusion, the IKK α kinase can positively or negatively regulate cell signalling and pro- and anti-inflammatory gene expression by phosphorylating diverse substrates, and could thus play a complex role in atherogenesis as well.

As haematopoietic cells are crucial players in the inflammatory reactions driving atherosclerosis, this study investigated the role of haematopoietic IKK α kinase activation in haematopoiesis and atherogenesis after transplantation of atherosclerosis-prone *Apoe*^{-/-} mice with bone marrow carrying an activation-resistant *Ikk α* ^{AA/AA} mutant [22].

Materials and Methods

Nomenclature

The letter format of all gene and protein notations in this manuscript is in accordance with internationally agreed gene/protein nomenclature guidelines: all letters of human genes/proteins are in uppercase, whereas for mouse genes/proteins, only the first letter is in uppercase. Gene names are in italics.

Mouse model, bone marrow (BM) transplantation and ethics statement

C57BL/6 *Ikk α* ^{AA/AA} mice, which are homozygous for an activation-resistant mutant of *Ikk α* through replacement of the serines 176/180 in the kinase activation loop with alanines [22], were crossed with atherosclerosis-prone C57BL/6 *Apoe*^{-/-} to generate *Ikk α* ^{AA/AA} *Apoe*^{-/-} mice. BM cells (3×10^6 /mouse) from *Ikk α* ^{AA/AA} *Apoe*^{-/-} mice or from *Ikk α* ^{+/+} *Apoe*^{-/-} littermate controls were flushed from femur and tibia marrow cavities and were subsequently administered to female C57BL/6 *Apoe*^{-/-} recipient mice by lateral tail vein injection one day after a lethal dose of whole-body irradiation (2×6.5 Gy). After four weeks of recovery, the mice were put on a high-fat diet containing 21% fat and 0.15% cholesterol (Altromin) for either 8 or 13 weeks, as indicated. All animal experiments were approved by local authorities (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, Germany; approval number 8.87-50.10.35.08.073) and complied with the German animal protection law. All surgery was performed under ketamine/xylazine anesthesia, and all efforts were made to minimize suffering.

Determination of chimerism

The degree of chimerism in BM-transplanted mice was determined by quantifying the mutated *Ikk α* ^{AA} allele relative to the wild-type *Ikk α* allele in genomic DNA isolated from blood cells. Real-time quantitative PCR analysis was performed using the Maxima SYBR Green qPCR Mastermix (Fermentas) in a thermal cycler 7900HT (Applied Biosystems) using specific primer pairs (Sigma-Aldrich): 5'-CCTCTCAGTGGCTCACCTTT and 5'-

CAATGTTCCACAAAAGATGTACAGAGACT (for *Ikk α*); 5'-CCTCTCAGTGGCTCACCTTT and 5'-CAATGTTCCCA-CAAACGCTGTACAGAGCGC (for *Ikk α ^{AA}*); 5'-CAAC-GAGCGGTTCCGATG and 5'-GCCACAGGATTCATACC-CAA (for β -Actin). β -Actin was used as a reference gene. The method was validated by analyzing a standard curve using genomic DNA from *Ikk α ^{AA/AA}Apoe^{-/-}* and *Ikk α ^{+/+}Apoe^{-/-}* blood cells, mixed at different ratios.

Lipid measurement in blood serum

Cholesterol and triglyceride levels in the blood serum were quantified using enzymatic assays (Cobas, Roche) according to the manufacturer's protocol. High-density (HDL), low-density (LDL) and very low-density (VLDL) cholesterol profiles were determined after HPLC-based fractionation of pooled serum samples using a Superose 10/300GL column followed by in-line cholesterol detection as described by Parini *et al.* [23].

Haematopoietic profiling and serum cytokine quantification

Lymph nodes, spleen, thymus and BM were harvested and a single-cell suspension was prepared and filtered over a 70 μ m cell strainer (Greiner). Splenocytes, BM cells and EDTA-buffered blood, obtained by retro-orbital puncture, were treated with erythrocyte lysis buffer (0.155 M NH₄Cl, 10 mM NaHCO₃) at room temperature. All cell suspensions were washed with HANKS Complete buffer containing 1 \times HBSS with 0.3 mM EDTA and 0.1% BSA, and stained with combinations of antibodies to Cd45, Cd11b, MhcII, Cd19, Cd3, Cd62L or Cd25 (BD Bioscience), to Cd11b, Cd115, Gr1, Cd3, Cd4, Cd8a, Cd25, Foxp3, Cd44, Cd11c or 440c (eBioscience), or to B220 (BioLegend). Intracellular labelling of Foxp3 was performed using the mouse regulatory T-cell staining kit (eBioscience) according to the manufacturer's protocol. Flow cytometric analysis was performed using a FACSCanto II and FACSDiva software (BD Biosciences) after appropriate fluorescence compensation, and leukocyte subsets were gated using FlowJo software (Treestar). B-cells were identified as Cd45⁺Cd19⁺ or B220⁺ as indicated; T-cells as Cd45⁺Cd3⁺; naive T-cells as Cd44^{low}Cd62L^{high} T-cells; effector memory T-cells as Cd44^{high}Cd62L^{low} T-cells; central memory T-cells as Cd44^{high}Cd62L^{high} T-cells; regulatory T-cells (T_{reg} cells) as Cd4⁺Cd25⁺Foxp3⁺ T-cells; neutrophils as Cd45⁺Cd115⁺Gr1^{high}, monocytes as Cd45⁺Cd115⁺; conventional DCs (cDCs) as Cd45⁺Cd11c⁺MhcII⁺; and plasmacytoid DCs (pDCs) as Cd45⁺Cd11c⁺Cd11b⁻440c⁺.

Cytokine levels in the blood serum were measured by flow cytometry using the BD Cytometric Bead Array Mouse Inflammation Kit (for Tnf- α , Mcp1, Il6, Ifn- γ , Il12 and Il10; BD-Pharmingen). In addition, Il10 levels were measured using a mouse Il10 Quantikine ELISA kit (R&D Systems).

Atherosclerotic lesion analysis using histology and immunofluorescence staining

For atherosclerotic lesion analysis, the aortic root and thoraco-abdominal aorta were stained for lipid depositions with Oil-Red-O. In brief, the heart with aortic root was embedded in Tissue-Tek for cryo sectioning. Atherosclerotic lesions were quantified in 5 μ m transverse sections and averages were calculated from 3–5 sections. The aorta was opened longitudinally, mounted on glass slides and en face-stained. Macrophages, smooth muscle cells (SMCs) and T-cells in the atherosclerotic lesions were visualized by immunofluorescent staining for Mac2 (Cedarlane), Sma (Dako) and Cd3 (AbD Serotec), respectively, followed by a FITC- or Cy3-

conjugated secondary antibody staining (Jackson ImmunoResearch). Appropriate IgG antibodies were used as isotype controls. Nuclei were counterstained by 4',6-diamidino-2-phenylindol (DAPI). Neutrophil presence was examined by Naphthol-AS-D-chloroacetate Esterase (ASDCL) staining. Apoptotic nuclei were detected by terminal deoxynucleotidyl nick-end labelling (TUNEL-kit, Roche). Intracellular lipid deposits in aortic root lesions were stained using Nile Red (N-3013, Sigma). All images were recorded with a Leica DMLB fluorescence microscope and CCD camera. The quantification of lesion size and composition was performed using Diskus analysis software (Hilgers), whereas the Nile Red stainings were analyzed with help of Image J software. All analyses were performed without prior knowledge of the genotype.

To explore potential qualitative effects on atherosclerosis, the aortic root lesions were classified according to phenotype, as previously described [11]. Three categories were distinguished: (1) early lesions, containing only foam cells, (2) intermediate-type lesions, presenting foam cells, some necrosis and a fibrotic cap, (3) advanced lesions, showing extended fibrosis and necrosis and infiltration of the plaque into the media.

Preparation and labelling of oxLDL

OxLDL was prepared by oxidation of LDL (Calbiochem) with a 50 nM copper sulphate solution for 4 hours at 37°C for mildly oxidized LDL and overnight for heavily oxidized LDL, followed by purification over a PD 10 column (GE Healthcare). For lipid uptake experiments heavily oxidized LDL was labelled with 1,10-dioctadecyl-3,3,3030-tetramethylindocyanide perchlorate (Dil). After incubation of 0.5 mg/ml oxLDL with 20 μ L of Dil (stock 3 mg/ml in DMSO) overnight at 37°C, the Dil-labelled oxLDL was purified over a PD 10 column and stored at 4°C for a maximum of 2 weeks.

BM-derived macrophages, nuclear extracts and NF- κ B p65 DNA-binding ELISA

BM-derived macrophages were generated as previously described [24]. Briefly, BM from the femurs and tibiae was flushed with ice-cold PBS using a 27-G needle, resuspended in PBS by repeated vigorous pipetting and filtered using a 70 μ m cell strainer (BD Biosciences). The filtered solution was centrifuged, the resulting pellet resuspended in culture medium and the cells plated on 15 cm untreated culture dishes (Greiner). BM-derived macrophages from cryopreserved BM-cells were generated as previously described [25]. Culturing and stimulation of BM-derived macrophages were performed in RPMI 1640 (+L-Glutamin) containing 10 mM Hepes, 10% FCS, 15% L929-cell-conditioned medium and 100 U/ml gentamycin. After 7 days of culturing, differentiated macrophages were used for stimulation experiments and transferred onto untreated 6-well dishes (Greiner). The cells were left for 24 hours to adhere and were then stimulated with 100 ng/ml lipopolysaccharide (LPS) (Sigma-Aldrich), 10 ng/ml mouse Tnf- α (Peprtech) or 50 μ g/ml mildly oxidized LDL, as indicated.

Nuclear extracts were isolated as described [11]. Briefly, BM-derived macrophages were washed once with PBS and scraped of the culture dish using PBS with 5 mM EDTA. The cells were centrifuged and the cell pellet was resuspended in 100 μ l buffer A (10 mM Hepes pH 7.8, 1.5 mM MgCl₂, 0.5 mM DTT and 1 \times Complete EDTA-free protease inhibitor cocktail (Roche)). After 2 min incubation on ice, 100 μ l of buffer A supplemented with 1.28% NP40 was added to the cell suspension and incubated on ice for 10 min. The cells were vortexed for 10 sec and centrifuged for 10 min at 2000 rpm. The supernatant was removed, the pellet

dissolved in 50 μ l buffer B (20 mM Hepes pH 7.8, 420 mM NaCl; 1,2 mM MgCl₂, 0.2 mM EDTA, 25% glycerol, 0.5 mM DTT and 1 \times Complete EDTA-free protease inhibitor cocktail (Roche)) and incubated for 30 min on ice. Every 5 min, the sample was vortexed thoroughly. Then the solution was centrifuged for 15 min at 4000 rpm and the supernatant, being the nuclear lysate, was snap-frozen at -80°C . Protein concentration was determined using the Quick Start Bradford Protein Assay (Biorad).

NF- κ B p65 DNA-binding activity in equal amounts of nuclear extracts was quantified using an oligonucleotide-based ELISA (TransAM NF- κ B p65 ELISA, Active Motif) according to the supplier's instructions. Absorbance values were corrected for background by incubation with lysis buffer only.

In vitro macrophage foam cell formation and cytokine secretion

To quantify the uptake of DiI-labelled heavily oxidized LDL by BM-derived macrophages, macrophages were plated on 24-well plates and incubated overnight at 37°C . The next day, non-adherent cells were rinsed off with PBS and medium containing 1 μ g/ml or 10 μ g/ml DiI-oxLDL was added. To analyze whether oxLDL uptake occurred in an actin-dependent way, controls were pre-incubated for 1 h with 10 mM cytochalasin D, followed by a stimulation with 10 μ g/ml DiI-oxLDL and 10 mM cytochalasin D. The cells were stimulated for 3 or 24 hours as indicated, washed with PBS and stained with F4/80 (clone BM8, eBioscience). Flow cytometric analysis was performed using a FACSCanto II and the data were analyzed using FlowJo software (Treestar). Data were calculated by subtracting the cell autofluorescence (cells without diI-oxLDL incubation) from the fluorescence of the diI-oxLDL-treated samples and were expressed as geometric mean fluorescence intensity (gMFI).

To measure cytokine and chemokine secretion from BM-derived macrophages, cells were plated in 6-well plates, left for 24 h to adhere and were then stimulated with 10 ng/ml mouse Tnf- α (Peprotech) or 50 μ g/ml heavily oxidized LDL. As control unstimulated cells were included. After 24 h the medium was harvested from the cells, and cytokine and chemokine levels were measured by flow cytometry using the BD Cytometric Bead Array Mouse Inflammation Kit (BD-Pharmingen). In addition, Mcp1 levels were measured using a mouse Mcp1 ELISA (DY479, R&D Systems).

Statistical analysis

All statistical analyses were performed using GraphPad Prism (GraphPad Software Inc.). Data are represented as means \pm SEM and were analyzed by 2-tailed Student's t-test or 2-way ANOVA with Bonferroni post-test, as appropriate. $P < 0.05$ was considered statistically significant.

Results

Bone marrow-specific loss of Ikk α kinase activation affects B- and T-lymphocyte populations

To study the role of IKK α kinase activation in haematopoiesis in the context of atherosclerosis, BM was isolated from *Ikk α ^{+/-}Apoe^{-/-}* or *Ikk α ^{AA/AA}Apoe^{-/-}* mice, the latter carrying a non-activatable mutant of Ikk α through replacement of serines 176/180 in its activation loop with alanine residues [22]. After transplantation of this BM into lethally irradiated *Apoe^{-/-}* mice and a recovery period of four weeks, the mice received a high-cholesterol diet for 13 weeks to accelerate atherosclerosis. Quantitative real-time PCR for the *Ikk α ^{AA/AA}* vs *Ikk α ^{+/+}* allele in white blood cells of the transplanted recipient mice indicated that

on average 96.1% (± 1.2) of leukocytes carried the mutant *Ikk α ^{AA/AA}* allele, confirming a successful engraftment.

Interestingly, although total leukocyte counts were unaffected, *Ikk α ^{AA/AA}Apoe^{-/-}* BM chimeras showed a significantly reduced Cd19⁺ B-cell population in peripheral blood (Figure 1A, Table 1). A similar decrease in B-cell number was seen in the BM and lymph nodes of the *Ikk α ^{AA/AA}Apoe^{-/-}* BM chimeras, whereas no difference was observed in the spleen B-cell population (Figure S1).

In addition, also Cd3⁺Cd4⁺Cd25⁺Foxp3⁺ regulatory T-cells (T_{reg}), which are associated with atheroprotection [26], were found to be significantly reduced in the Cd3⁺ T-cell population of the peripheral blood, thymus and secondary lymphoid organs of the *Ikk α ^{AA/AA}Apoe^{-/-}* -transplanted mice (Figure 1B). Also among Cd45⁺ leukocytes, T_{reg} frequency was markedly decreased in blood and spleens of the *Ikk α ^{AA/AA}Apoe^{-/-}* BM chimeras (Figure 1B). However, this was not observed in the lymph nodes (Figure 1B), which showed a significant overall increase of Cd3⁺ T-cells in the leukocyte population (Figure S1B).

No changes were observed in the relative proportions of Cd4⁺ and Cd8a⁺ T-cell subsets in blood or lymphoid organs (Figure 1A, Figure S1). However, spleen and lymph nodes of *Ikk α ^{AA/AA}Apoe^{-/-}* -transplanted mice displayed a significant increase in the Cd3⁺Cd44^{low}Cd62L^{high} naive T-cell population, whereas Cd3⁺Cd44^{high}Cd62L^{low} effector memory T-cells, which mediate effector functions in inflamed tissue [27], were significantly reduced (Figure 1C, Figure S2). Also, the Cd3⁺Cd44^{high}Cd62L^{high} central memory T-cell population, associated with the successive production of effector T-cells [27], was significantly decreased among splenic T-lymphocytes and total leukocytes (Figure S3).

Furthermore, relative frequencies of Cd115⁺Gr1⁺ neutrophils, Cd115⁺ monocytes and both Gr1^{high} and Gr1^{low} monocyte subsets in the peripheral blood were unchanged (Table 1). Also, splenocytes showed comparable frequencies of Cd11c⁺MhcII⁺ conventional dendritic cells (cDCs) and Cd11c⁺Cd11b⁻440c⁺ plasmacytoid DCs (pDCs) (Figure 1D). Nonetheless, expression of the activation marker MhcII was significantly reduced on splenic pDCs of *Ikk α ^{AA/AA}Apoe^{-/-}* BM chimeras (Figure 1D).

A similar effect on B- and T-cell populations was observed in a non-atherosclerotic context. C57BL/6 mice transplanted with *Ikk α ^{AA/AA}* BM displayed a significantly reduced B-cell population in lymph nodes compared to controls, whereas both Cd4⁺ and Cd8a⁺ T-cell subsets were increased (Figure S4A,B). Similarly as observed before, T_{reg} lymphocytes were markedly decreased (Figure S5). Altogether, these findings indicate an important role for Ikk α kinase activity in haematopoiesis, with reduced B-cells and T_{reg} lymphocytes upon haematopoietic expression of an *Ikk α ^{AA/AA}* mutant.

Atherosclerotic lesions are unaltered in *Ikk α ^{AA/AA}Apoe^{-/-}* bone marrow chimeras

After 13 weeks of high-cholesterol diet, *Ikk α ^{AA/AA}Apoe^{-/-}* and *Ikk α ^{+/+}Apoe^{-/-}* BM chimeras were sacrificed and lipid levels in serum and the extent of atherosclerosis in the aorta and aortic root were analyzed. Whereas body weight and serum triglyceride values were similar, cholesterol levels were significantly increased in *Ikk α ^{AA/AA}Apoe^{-/-}* vs *Ikk α ^{+/+}Apoe^{-/-}* BM-transplanted *Apoe^{-/-}* mice (Figure 2A,B). This could be attributed to an increase in VLDL and LDL lipoprotein fractions, as shown by a cholesterol analysis after HPLC-based lipoprotein size separation of pooled serum samples (Figure 2C). Despite these differences in cholesterol levels, atherosclerotic lesion sizes in the aorta and aortic root were comparable in *Ikk α ^{AA/AA}Apoe^{-/-}* and *Ikk α ^{+/+}Apoe^{-/-}* BM chimeras (Figure 2D,E). To explore potential qualitative effects on atherosclerosis, the aortic root lesions were phenotypically




Figure 1. *Ikkα^{AA/AA}Apoe^{-/-}* BM-chimeras have less B-cells, T_{reg} and effector memory T-cells, and more naive T-cells. Shown is flow cytometric analysis of peripheral blood, thymus and secondary lymphoid organs of *Apoe^{-/-}* mice transplanted with *Ikkα^{AA/AA}Apoe^{-/-}* or *Ikkα^{+/+}Apoe^{-/-}* BM and receiving a high-cholesterol diet for 13 weeks. (A) Cd19⁺ B-cell and Cd3⁺ T-cell populations as percentage of Cd45⁺ leukocytes, and Cd4⁺ and Cd8a⁺ T-cell subsets as percentage of Cd3⁺ T-cells in peripheral blood. (B) Cd3⁺Cd4⁺Cd25⁺Foxp3⁺ regulatory T-cell (T_{reg}) levels as percentage of Cd3⁺ T-cells and Cd45⁺ leukocytes. (C) Cd3⁺Cd44^{low}Cd62L^{high} naive T-cells and Cd3⁺Cd44^{high}Cd62L^{low} effector memory T-cells as percentage of Cd3⁺ T-cells and Cd45⁺ leukocytes. Left Y-axes belong to naive T-cells, right Y-axes to effector memory T-cells. (D) Cd11c⁺Mhcll⁺ conventional dendritic cells (cDCs) and Cd11c⁺Cd11b⁻440c⁺ plasmacytoid DCs (pDCs) as percentage of Cd45⁺ leukocytes (left). Surface expression of Mhcll on splenic cDCs and pDCs (right). (A–D) All graphs represent the mean ± SEM (n = 18–19); 2-tailed t-test, *P<0.05, **P<0.01, ***P<0.001. doi:10.1371/journal.pone.0087452.g001

classified into early, intermediate-type and advanced lesions, as previously described [11]. Again, no differences were found between both groups (Figure 2F). Also, the cellular composition of aortic root lesions was comparable, presenting an equal content of macrophages (Mac2⁺) and SMCs (Sma⁺) as shown by immunofluorescent stainings (Figure 3A,B). Similarly, no significant differences were observed in lesional Cd3⁺ T-lymphocyte content

(Figure 3C). No neutrophils could be detected in any of the aortic root lesions. Finally, necrotic core sizes were comparable (Figure 4A), and no significant differences were found in the content of TUNEL⁺ apoptotic cells and apoptotic macrophages in aortic root lesions of *Ikkα^{AA/AA}Apoe^{-/-}* and *Ikkα^{+/+}Apoe^{-/-}* BM chimeras (Figure 4B,C).

Table 1. Leukocyte numbers and frequencies of leukocyte subsets in *ApoE*^{-/-} mice transplanted with *Ikk α ^{AA/AA}ApoE*^{-/-} or *Ikk α ^{+/+}ApoE*^{-/-} BM.

	<i>Ikkα^{+/+}ApoE</i> ^{-/-} BM	<i>Ikkα^{AA/AA}ApoE</i> ^{-/-} BM
Leukocytes ($\times 10^3/\mu\text{l}$ blood)	7.9 \pm 0.6	7.1 \pm 0.3
Monocytes (% of leukocytes)	7.9 \pm 0.5	8.7 \pm 0.6
Gr1 ^{high} monocytes (% of monocytes)	66.0 \pm 2.0	68.1 \pm 2.7
Gr1 ^{high} monocytes (% of leukocytes)	5.2 \pm 0.3	5.7 \pm 0.3
Gr1 ^{low} monocytes (% of monocytes)	29.8 \pm 2.1	26.9 \pm 2.4
Gr1 ^{low} monocytes (% of leukocytes)	2.4 \pm 0.3	2.5 \pm 0.3
Neutrophils (% of leukocytes)	19.0 \pm 1.3	20.4 \pm 1.2

Peripheral blood leukocyte counts were determined after 8 weeks of high-fat diet (n=8). Leukocyte subset frequencies were quantified by flow cytometry after 13 weeks of high-fat diet (n=18–19).

doi:10.1371/journal.pone.0087452.t001

To investigate potential effects on earlier stages of atherosclerosis, a similar study was performed after a high-cholesterol diet fed for only 8 weeks. Successful engraftment of *Ikk α ^{AA/AA}ApoE*^{-/-} BM into lethally irradiated *ApoE*^{-/-} mice was again confirmed by quantitative real-time PCR, showing the mutant *Ikk α ^{AA/AA}* allele to be present in 94.3% (\pm 2.7) of blood leukocytes. After this shorter period of high-fat diet, no differences were obtained in body weight or lipid levels in the blood serum, and also HPLC-based lipoprotein fractionation of pooled serum samples showed comparable HDL-, LDL- and VLDL-associated cholesterol peaks (Figure 5A–C). Similarly as for the 13 week-high-fat diet, *Ikk α ^{AA/AA}ApoE*^{-/-} and *Ikk α ^{+/+}ApoE*^{-/-} BM chimeras presented comparable atherosclerotic lesion sizes in the aorta and aortic root (Figure 5D,E). Lesions were reduced in size with 39% and 56% in aorta and aortic root, respectively, compared to the longer diet course, as can be expected. Also, classification of the plaques into early, intermediate or advanced stages revealed comparable lesion phenotypes in *Ikk α ^{AA/AA}ApoE*^{-/-} and *Ikk α ^{+/+}ApoE*^{-/-} BM-transplanted *ApoE*^{-/-} mice, although the lesions were less advanced compared to the 13 week-diet study (Figure 5F).

In summary, these data indicated that the transplantation of *Ikk α ^{AA/AA}ApoE*^{-/-}-mutant BM does not affect the size, phenotype or cellular content of atherosclerotic lesions in atherosclerosis-prone *ApoE*^{-/-} mice.

Haematopoietic knock-in of the *Ikk α ^{AA/AA}* mutant does not affect systemic inflammatory gene expression in *ApoE*-deficient mice

The canonical NF- κ B pathway has been shown to play an important role in controlling atheroprotection, at least partly by balancing anti- and pro-inflammatory processes in macrophages [11]. Canonical NF- κ B activation is dependent on IKK β and IKK γ , but does not require IKK α kinase activity for IKK-mediated I κ B- α phosphorylation and degradation with subsequent NF- κ B activation [12,13]. On the other hand, IKK α has been shown to terminate LPS-induced NF- κ B activity in macrophages by promoting the phosphorylation and degradation of the NF- κ B isoform p65, thereby abrogating p65-mediated gene transcription [19]. Therefore, we aimed to examine the direct effect of the *Ikk α ^{AA/AA}* knock-in mutation on canonical NF- κ B activity in the context of atherosclerosis by studying the DNA binding capacity of p65 in nuclear extracts of *Ikk α ^{AA/AA}ApoE*^{-/-} vs *Ikk α ^{+/+}ApoE*^{-/-} BM-derived macrophages *in vitro*. Unexpectedly, the *Ikk α ^{AA/AA}*

knock-in mutation did not enhance or prolong p65 activity in *ApoE*-deficient macrophages upon stimulation with Tnf- α or oxidized LDL (oxLDL), i.e. mimicking inflammatory or atherogenic challenges, and even slowed down Tnf- α -induced p65 activation. No differences were observed in LPS-induced p65 activity in *Ikk α ^{AA/AA}ApoE*^{-/-} vs *Ikk α ^{+/+}ApoE*^{-/-} BM-derived macrophages (Figure 6A).

Furthermore, the concentrations of the inflammatory proteins Tnf- α , Il-6 and M α p1 in supernatants of Tnf- α - or oxLDL-stimulated *Ikk α ^{AA/AA}ApoE*^{-/-} and *Ikk α ^{+/+}ApoE*^{-/-} BM-derived macrophages were not significantly different, although *Ikk α ^{AA/AA}* knock-in significantly enhanced the basal secretion of M α p1, in contrast to Tnf- α or Il-6 (Figure 6B). Neither Tnf- α nor oxLDL were able to induce secretion of Il-10 or Il-12p70 *in vitro*, although Il-12p70 secretion was found to be significantly higher in oxLDL-stimulated macrophages upon *Ikk α ^{AA/AA}* knock-in (Figure S6). In addition, quantification of Tnf- α , Il-6 and M α p1 in serum of *Ikk α ^{AA/AA}ApoE*^{-/-} vs *Ikk α ^{+/+}ApoE*^{-/-} BM chimeras after 8 weeks of high-fat diet did not reveal significant differences (Figure 6C), whereas the cytokines Ifn- γ , Il-12 and Il-10 remained below the detection limit in both groups.

Given the importance of lipid uptake by macrophages in atherosclerotic lesions, we examined a possible effect of *Ikk α ^{AA/AA}* knock-in on macrophage foam cell formation *in vitro*. With 2 different incubation times and oxLDL doses, we did not observe a significant difference in oxLDL uptake by *Ikk α ^{AA/AA}ApoE*^{-/-} vs *Ikk α ^{+/+}ApoE*^{-/-} BM-derived macrophages (Figure 7A). Cytochalasin D severely reduced the oxLDL-associated fluorescence signal, indicating that oxLDL was actively taken up by the cells in an actin-dependent way and not merely binding the cell surface (Figure 7A). Next, we quantified lipid deposits in aortic root lesions of *Ikk α ^{AA/AA}ApoE*^{-/-} and *Ikk α ^{+/+}ApoE*^{-/-} BM chimeras after 13 weeks of high-cholesterol diet using Nile Red staining, but no difference were observed (Figure 7B,D). Also, quantification of Nile Red-positive macrophages after co-staining for Mac2 together with Nile Red dye revealed comparable intracellular lipid deposits in lesional macrophages and an equal amount of lipid-laden macrophages (Figure 7C,D).

In conclusion, these data show that knock-in of *Ikk α ^{AA/AA}* in an *ApoE*^{-/-} background does not enhance NF- κ B activity or majorly influence the secretion of important inflammatory proteins from Tnf- α - or oxLDL-stimulated macrophages, nor does it significantly affect macrophage foam cell formation.

Discussion

Atherosclerosis is characterized by a chronic inflammation of the vessel wall and all leukocyte subsets, including B- and T-lymphocytes, monocytes and monocyte-derived macrophages, neutrophils and DCs, contribute in their own specific ways to the pathogenesis of this widespread disease [1,2]. Therefore, we investigated the effect of a BM-specific non-activatable *Ikk α ^{AA}* knock-in on haematopoiesis in conditions of atherosclerosis and identified a significant reduction in the B-cell population in the blood and lymph nodes of hyperlipidaemic *Ikk α ^{AA/AA}ApoE*^{-/-} BM chimeras in comparison with *Ikk α ^{+/+}ApoE*^{-/-} BM-transplanted *ApoE*^{-/-} controls (Figure 1A, Figure S1). Comparable results were obtained in a non-atherosclerotic context, with a significantly reduced B-cell population in lymph nodes of C57BL/6 mice transplanted with *Ikk α ^{AA/AA}* vs *Ikk α ^{+/+}* BM (Figure S4), and are consistent with earlier observations of a reduced mature B-cell population in secondary lymphoid organs of *Ikk α ^{AA/AA}* knock-in mice and in *Ikk α ^{-/-}* and *Ikk α ^{AA/AA}* BM chimeras [15,28]. Similar effects were seen in *Baff*^{-/-} mice [29] and revealed a crucial role




Figure 2. Knock-in of *Ikkα*^{AA/AA} in haematopoietic cells does not influence advanced atherosclerosis in *Apoe*^{-/-} mice. *Apoe*^{-/-} mice were transplanted with *Ikkα*^{AA/AA}*Apoe*^{-/-} or *Ikkα*^{+/+}*Apoe*^{-/-} BM and received a high-cholesterol diet for 13 weeks before analysis. (A,B) Body weight (A) and lipid analysis in blood serum (B) (n = 18). (C) Cholesterol levels after HPLC-based size fractionation of pooled blood serum samples. (D,E) Atherosclerotic lesion sizes in the aorta (D) and aortic root (E) (n = 16–19). Representative pictures of Oil-Red-O⁺ lipid depositions in aorta and aortic root are shown. Scale bar = 500 μ m. (F) Classification of aortic root lesions according to their severity. Shown is the plaque distribution as percentage of the total number of lesions examined (n = 18–27). (A,B,D,E) Graphs represent the mean \pm SEM; 2-tailed t-test, ***P < 0.001. doi:10.1371/journal.pone.0087452.g002

for the non-canonical Baff-Baffr-Nik-Ikk α pathway in B-cell maturation and survival. Our observation that the Cd19⁺ B-cell population is also significantly decreased in the BM of *Ikkα*^{AA/AA}*Apoe*^{-/-}-transplanted *Apoe*^{-/-} mice (Figure S1) suggests that the Ikk α kinase activity is also important in BM B-cell development. This corresponds to recent findings of Balkhi and colleagues, who

identified a reduction in the Cd19⁺, B220⁺ and Cd19⁺B220⁺ B-cell population in the BM of kinase-dead *Ikkα* (*Ikkα*^{KA/KA}) knock-in mice and *Ikkα*^{KA/KA} BM chimeras, and also revealed less B220⁺Cd19⁺ B-cells in the BM of irradiated *Rag*^{-/-} mice reconstituted with *Ikkα*^{-/-} fetal liver cells [30]. Thus, our data support this important role for Ikk α kinase activity in early B-cell




Figure 3. Knock-in of *Ikkα*^{AA/AA} in haematopoietic cells does not influence the cellular composition of atherosclerotic lesions. Immunofluorescent stainings of aortic roots from *Apoe*^{-/-} mice reconstituted with *Ikkα*^{AA/AA} *Apoe*^{-/-} or *Ikkα*^{+/+} *Apoe*^{-/-} BM and receiving a high-fat diet for 13 weeks. **(A–C)** Quantification of Mac2⁺ macrophages (A, n = 17–18), Sma⁺ SMCs (B, n = 16–17) and Cd3⁺ T-cells (C, n = 7–8) as percentage of all plaque cells (left) and relative to the plaque area (right). Graphs represent the mean ± SEM. Representative pictures are shown. Scale bar = 100 μm. doi:10.1371/journal.pone.0087452.g003

development in the BM, which was revealed to involve both canonical and non-canonical NF-κB pathways [30].

Secondly, we observed a consistent increase in the Cd62L^{high}Cd44^{low} naive T-cell population in secondary lymphoid organs of *Ikkα*^{AA/AA} *Apoe*^{-/-} BM chimeras, whereas Cd62L^{low}Cd44^{high} effector memory T-cells were decreased (Figure 1C). This corresponds with a previous observation of Mancino and colleagues, who revealed that *Ikkα* kinase activity in DCs is crucial for antigen-specific priming of naive T-cells in an *in vivo* delayed-type hypersensitivity model [31]. Similar effects on the ratio of naive *vs* effector memory T-cells were seen in mice deficient for *Nik*, the kinase activating *Ikkα* in the non-canonical NF-κB pathway [32]. Likewise, *Nik*^{aly/aly} mice, which carry a natural *Nik* mutant (*Nik*^{aly}) unable to bind *Ikkα* and associated with reduced NF-κB activation [33–35], presented with reduced T-cell

effector cytokine expression, which was ascribed to a *Nik*-deficiency in thymic DCs rather than to an intrinsic T-cell defect [36]. Despite equal DC numbers in the thymus of *Nik*^{aly/aly} and *Nik*^{+/+} mice, thymic *Nik*^{aly/aly} DCs showed a decreased expression of typical activation markers [36]. Similarly, also splenic *Nik*^{aly/aly} DCs expressed a considerably lower level of MhcII compared to *Nik*^{aly/+} DCs [37], suggesting an inability of *Nik*^{aly/aly} DCs to deliver T-cell costimulatory signals and contribute to the development of effector T-cells [36]. In line with this, our *Ikkα*^{AA/AA} *Apoe*^{-/-} BM chimeras displayed a significantly reduced MhcII expression on splenic pDCs (Figure 1D). Very recently, an increased ratio of naive *vs* effector memory T-cells was also seen in *Nik*^{-/-} BM chimeras, but was linked with a cell-intrinsic role of *Nik* in the generation or maintenance of effector memory T-cells [38]. Given these new findings together with the previous observations of




Figure 4. Knock-in of *Ikkα^{AA/AA}* in haematopoietic cells does not influence apoptosis in atherosclerotic lesions. Analysis of aortic root lesions of *Apoe^{-/-}* mice transplanted with *Ikkα^{AA/AA}Apoe^{-/-}* or *Ikkα^{+/+}Apoe^{-/-}* BM and receiving a high-fat diet for 13 weeks. (A) Quantification of necrotic cores as percentage of plaque area. (B–C) Quantification of apoptotic cells (Tunel⁺, B) and apoptotic macrophages (Tunel⁺Mac2⁺, C) as percentage of all plaque cells. Graphs represent the mean ± SEM (n = 10–12). doi:10.1371/journal.pone.0087452.g004

Mancino *et al.* [31], the relative importance of cell-intrinsic *vs* DC-mediated effects on the increased ratio of naive *vs* effector memory T-cells in our *Ikkα^{AA/AA}* BM chimeras remains to be investigated.

In addition to reduced effector memory T-cells, *Ikkα^{AA/AA}Apoe^{-/-}* BM chimeras displayed a significantly reduced T_{reg} population (Figure 1B, Figure S5). T_{reg} cells develop in the thymus and in peripheral sites from naive CD4⁺ T-cells. Initially, defective alternative NF-κB activation in the thymic stroma and a disorganized thymic structure in *Nik^{aly/aly}* mice was associated with a defective establishment of self-tolerance and reduced T_{reg} numbers [39]. Later, a study of single *Nik^{-/-}* *vs* mixed *Nik^{-/-}/Nik^{+/+}* BM chimeras indicated an additional cell-intrinsic role for *Nik* in the maintenance of peripheral T_{reg} T-cells [38]. Also, at least part of the T_{reg} defect in *Nik^{aly/aly}* mice was attributed to the reduced capacity of *Nik^{aly/aly}* DCs to trigger T_{reg} expansion and survival *in vitro* [37], and both NIK and IKKα were shown to be required in human DCs to trigger the development of T_{reg} cells from naive CD4⁺ T-cells *in vitro* [40]. Subsequently, pDC-triggered

T_{reg} development from naive T-cells was associated with the induction of indoleamine 2,3-dioxygenase in pDCs by NIK-mediated non-canonical NF-κB activation [40–43]. With *Ikkα* a crucial player in this alternative NF-κB pathway, our data now directly confirm for the first time a role for haematopoietic *Ikkα* kinase activation in the generation of T_{reg} cells *in vivo*. However, the relative importance of T_{reg}-intrinsic *vs* DC-mediated mechanisms remain to be investigated, both in the periphery as thymus, given that peripheral DCs can migrate into the thymus to actively contribute to thymic T_{reg} generation [44]. Of note, the reduced T_{reg} population in *Ikkα^{AA/AA}Apoe^{-/-}* BM chimeras could be associated with the increased serum levels of VLDL observed in these mice, as depletion of T_{reg} T-cells was recently discovered to enhance VLDL levels through reduced VLDL clearance [45].

Despite the clear effects of a BM-specific *Ikkα^{AA/AA}Apoe^{-/-}* knock-in on haematopoiesis and the enhanced VLDL levels, no differences were observed in the size, phenotype and cellular composition of atherosclerotic lesions in hyperlipidaemic *Apoe^{-/-}* mice transplanted with *Ikkα^{AA/AA}Apoe^{-/-}* or *Ikkα^{+/+}Apoe^{-/-}* BM (Figure 2–5). The influence of the reduced B-cell population in the *Ikkα^{AA/AA}Apoe^{-/-}* BM chimeras on atherosclerosis is unclear. On the one hand, an atheroprotective effect could be suggested based on the observation that a transplantation of *Ldlr^{-/-}* mice with B-cell deficient (*μMT*) BM aggravated atherosclerosis [46] and also several other studies indicated an atheroprotective role for B-cells [1,16]. However, different B-cell subsets have diverse functions in atherogenesis and B2 B-cells, in contrast to B1 B-cells, rather exacerbate atherosclerosis [16]. In this context, a lack of B2 B-cells, but a preserved B1 B-cell population was detected in mice with a deficiency of *Baff* [29] or *Baffr* [47], which can signal to NF-κB through *Ikkα*. This was associated with reduced atherosclerosis in *Baffr^{-/-}Apoe^{-/-}* or *Baffr^{-/-}* BM-transplanted *Ldlr^{-/-}* mice compared to controls [48,49]. Although B-cell subsets were not examined in our study, Senfleben *et al.* predominantly found a reduction in the mature IgM^{low}IgD^{high} B-cell population in *Ikkα^{AA/AA}* mice and *Ikkα^{AA/AA}* BM chimeras [15], with IgD being a surface marker of follicular B2 B-cells [16]. Thus, the reduced B-cell population in our *Ikkα^{AA/AA}Apoe^{-/-}* BM chimeras may by itself provide atheroprotective effects through a potential decrease in B2 B-cells. Regarding T-lymphocytes, effector memory T-cells are present in atherosclerotic lesions [1] and were shown to positively correlate with the extent of atherosclerosis in atherogenic mice, whereas naive T-cells were inversely correlated with plaque size [50]. Furthermore, T_{reg} T-cells have been shown to mediate atheroprotective functions [1,26]. Therefore, pro-atherogenic effects of a reduction in the T_{reg} population in *Ikkα^{AA/AA}Apoe^{-/-}* BM chimeras may be compensated by atheroprotective effects of the observed relative increase of naive *versus* effector memory T-cells in these mice. Comparable results were seen upon deficiency of Cd40-Traf2/3/5 signalling in *Apoe^{-/-}* mice, which did not affect atherosclerosis despite an increase in both atheroprotective effector memory T-cells and atheroprotective T_{reg} cells in blood and secondary lymphoid organs [51]. Altogether, this suggests that simultaneous changes in lymphocyte subsets may completely balance individual atheroprotective and -protective effects, without any net effect on atherosclerosis, similarly as observed in our study.

As macrophages play an important role in the uptake of modified lipids in atherosclerotic lesions, we examined the effect of an *Ikkα^{AA/AA}* knock-in on macrophage intracellular lipid accumulation. However, no significant differences were observed *in vitro* or in atherosclerotic lesions *in vivo* (Figure 7), which is similar as previously observed for *Ldlr^{-/-}* mice with a myeloid-specific deletion of *Ikkβ* [11].




Figure 5. *Ikkα*^{AA/AA} knock-in in haematopoietic cells does not influence earlier stages of atherogenesis in *ApoE*^{-/-} mice. *ApoE*^{-/-} mice were transplanted with *Ikkα*^{AA/AA}*ApoE*^{-/-} or *Ikkα*^{+/+}*ApoE*^{-/-} BM and received a high-cholesterol diet for 8 weeks before analysis. (A,B) Body weight (A) and lipid analysis in blood serum (B) (n = 7–9). (C) Cholesterol levels after HPLC-based size fractionation of pooled blood serum samples. (D,E) Atherosclerotic lesion sizes in the aorta (D) and aortic root (E). Representative pictures of Oil-Red-O⁺ lipid depositions in aorta and aortic root are shown. Scale bar = 500 μ m. (F) Classification of aortic root lesions according to their severity. Shown is the plaque distribution as percentage of the total number of lesions examined (n = 22–26). (A,B,D,E) Graphs represent the mean \pm SEM. doi:10.1371/journal.pone.0087452.g005

Furthermore, the *Ikkα*^{AA/AA} knock-in mutation was previously shown to reduce macrophage apoptosis upon bacterial infection, which was associated with prolonged LPS-triggered NF- κ B p65 activation in BM-derived macrophages [19]. As apoptosis is an important process in atherogenesis, being atheroprotective in early stages of disease but associated with plaque necrosis and

atheroprotection in later phases [52], we investigated lesional apoptosis in *Ikkα*^{AA/AA}*ApoE*^{-/-} and *Ikkα*^{+/+}*ApoE*^{-/-} BM chimeras. However, no significant differences were observed in cellular or macrophage apoptosis, and also necrotic core sizes were comparable (Figure 4). Furthermore, we did not observe a differential activity of NF- κ B p65 upon LPS stimulation of *Ikkα*^{AA/AA}*ApoE*^{-/-}




Figure 6. *Ikkα*^{AA/AA} knock-in does not enhance or prolong NF- κ B p65 activity, or majorly influence cytokine expression in *Apoe*^{-/-} macrophages *in vitro*. (A) BM-derived macrophages from *Ikkα*^{AA/AA}*Apoe*^{-/-} and *Ikkα*^{+/+}*Apoe*^{-/-} mice were stimulated *in vitro* with 10 ng/ml Tnf- α , 50 μ g/ml of mildly oxidized LDL or 100 ng/ml LPS for the indicated time. Activation of p65 was quantified in nuclear extracts using a TransAm p65 assay. Graphs represent the mean \pm SEM (n=2); 2-way ANOVA with Bonferroni post-test, ***P<0.001. (B) BM-derived macrophages from *Ikkα*^{AA/AA}*Apoe*^{-/-} and *Ikkα*^{+/+}*Apoe*^{-/-} mice were stimulated *in vitro* for 24 h with 10 ng/ml Tnf- α or 50 μ g/ml heavily oxidized LDL. Cytokine concentrations in the supernatants are displayed for Tnf- α , Il-6 and Mcp1. Graphs represent mean \pm SEM (n=9 from 3 independent experiments); 2-way ANOVA with Bonferroni post-test, ***P<0.001. (C) Concentrations of Tnf- α , Mcp1 and Il-6 in serum of *Apoe*^{-/-} mice transplanted with *Ikkα*^{AA/AA}*Apoe*^{-/-} or *Ikkα*^{+/+}*Apoe*^{-/-} BM and receiving a high-fat diet for 8 weeks. Graphs represent the mean \pm SEM (n=7-9). doi:10.1371/journal.pone.0087452.g006

vs Ikkα^{+/+}*Apoe*^{-/-} BM-derived macrophages *in vitro*, and even detected a reduced response in p65 activation upon atherogenic (i.e. Tnf- α , oxLDL) exposure (Figure 6A). Although these differential observations between our study and the one from Lawrence and colleagues [19] are unexpected at first sight, a major difference between the two studies is the use of *Apoe*^{-/-} macrophages in our report. ApoE has been recognized as an important immunomodulator, which in macrophages promotes the anti-inflammatory M2 phenotype [53]. It is well-known that regulatory effects on NF- κ B signalling behave cell type-specific, also in the context of Ikk α -mediated NF- κ B regulation. For example, the *Ikkα*^{AA/AA} knock-in mutation did not affect LPS-induced canonical NF- κ B activation in BM-derived DCs [31], and even induced a small reduction in basal and LPS-induced NF- κ B activation in B-cells [15]. Thus, the dissimilar effects of an *Ikkα*^{AA/AA} knock-in mutation on LPS-induced NF- κ B p65 activity in macrophages in our study compared to the one from Lawrence *et al.* [19] could be due to differential macrophage phenotypes

induced by *Apoe*-deficiency or even by different culturing conditions. Furthermore, NF- κ B regulatory mechanisms are often stimulus-dependent, as also exemplified by the observation that an *Ikkα*^{AA/AA} knock-in did not affect Tnf- α -mediated NF- κ B activation in fibroblasts or mammary epithelial cells [22]. This could additionally explain why in our study no prolonged p65 activity could be observed in Tnf- α - or oxLDL-stimulated *Ikkα*^{AA/AA} macrophages *in vitro*.

Although the effect of Ikk α on NF- κ B stability in macrophages was only described for the isoforms p65 and c-Rel [19], also p50 activity has been reported in atherosclerotic lesions [54–56]. Even more, it has been suggested that p50-p50 homodimers represent the main NF- κ B activity during inflammation resolution, at least in a rat carrageenin-induced pleurisy model [8], which could correspond to the higher inflammatory phenotype of atherosclerotic lesions in *Ldlr*^{-/-} mice with a haematopoietic *p50* deficiency [57]. Although beyond the scope of this study, it would be interesting to perform a detailed characterization of canonical NF-




Figure 7. *Ikkα*^{AA/AA} knock-in does not influence macrophage lipid uptake. (A) Flow cytometric analysis of Dil-oxLDL uptake by BM-derived macrophages. Cells were incubated without or with Dil-oxLDL (1 μg/ml or 10 μg/ml) for 3 h or 24 h, as indicated. To test for actin-dependent uptake, additional controls were simultaneously treated with cytochalasin D (cytD), as indicated. Representative flow cytometric histograms are shown.

Graphs represent the mean \pm SEM (n = 3); 2-way ANOVA with Bonferroni post-test. (B–D) Intracellular lipid depositions in aortic root lesions were stained with Nile Red and co-stained with Mac2 in order to quantify lipid-laden macrophages. (B) Nile Red staining was quantified relative to the plaque area (left graph), and Nile Red⁺ cells were quantified as percentage of total plaque cells (right graph). (C) Lipid uptake by macrophages was quantified as Nile Red⁺Mac2⁺ area as % of Mac2⁺ area (left graph), and as Nile Red⁺Mac2⁺ cells as % of Mac2⁺-cells. (D) Shown are representative pictures from Nile Red staining (red fluorescence; left image). The middle and right image demonstrate Image J analyses. Displayed are the plaque area (thin red line), macrophage area (green), plaque cell nuclei (blue), Nile Red⁺ area (yellow) and Mac2⁺ Nile Red⁺ area (white, lipid deposits in macrophages). Graphs represent the mean \pm SEM (n = 5–6). doi:10.1371/journal.pone.0087452.g007

κ B isoform activity in different stages of atherosclerosis and investigate a potential regulation by the IKK α kinase under these specific atherosclerotic conditions *in vivo*. Simultaneously, the activity of non-canonical NF- κ B isoforms in the course of atherogenesis could be readdressed. Although a single study reported the absence of p52 and RelB activity in isolated human atherosclerotic plaque cells [55], a recent report identified a significant upregulation of IKK α and p52 during human monocyte-macrophage differentiation *in vitro*. This enables p52-mediated transcriptional repression under basal conditions, possibly preventing macrophage hyperactivation, but facilitates enhanced RelB-52 activity upon inflammation-induced RelB expression [58].

Our study did not reveal significant differences in inflammatory protein levels in the supernatants of Tnf α - or oxLDL-stimulated *Ikk α ^{AA/AA}Apoe^{-/-}* vs *Ikk α ^{+/+}Apoe^{-/-}* BM-derived macrophages, with the exception of Il-12 which showed a significant increase in oxLDL-stimulated macrophages upon *Ikk α ^{AA/AA}* knock-in (Figure 6B, Figure S6). Furthermore, we could not detect significant differences in macrophage-related inflammatory cytokine and chemokine levels in the serum of atherosclerotic *Ikk α ^{AA/AA}Apoe^{-/-}* vs *Ikk α ^{+/+}Apoe^{-/-}* BM chimeras (Figure 6C). Thus, despite the diverse roles of the Ikk α kinase in modulating gene expression in an NF- κ B-dependent or -independent manner [4,14], these functions do not seem strong enough in the context of atherogenesis to produce a major effect on systemic protein expression upon *Ikk α ^{AA/AA}* knock-in.

Furthermore, it is important to remember that the identification of novel IKK α substrates continuously extends the molecular pathways and biological processes affected by this kinase [4,14]. Also, atherosclerosis is influenced by many leukocyte subsets [1,2]. Therefore, it is conceivable that our overall zero effect of the BM-specific *Ikk α ^{AA}* mutation on atherosclerosis is at least partially the result of counterbalanced effects on different biological processes in macrophages or even different leukocyte subsets. For example, it would be interesting to study the effect of a DC- or T_{reg}-specific *Ikk α ^{AA/AA}* mutation on atherogenesis. Also, both IKK α and IKK β were shown to be important in neutrophil chemotaxis to HMGB1, a nuclear protein released by necrotic cells, but the functions of the IKK α kinase activity in neutrophil responses and molecular signalling in the context of inflammation and atherosclerosis have not yet been investigated. In addition, the role of IKK α in vascular cells remains to be investigated in more detail.

In conclusion, our data identify an important and previously unrecognized role for the haematopoietic Ikk α kinase activity in B- and T-cell homeostasis in conditions of atherosclerosis. However, the BM-specific *Ikk α ^{AA}* knock-in in atherosclerotic mice did not affect the size or phenotype of atherosclerotic lesions. This indicates that the diverse functions of Ikk α in haematopoietic cells may counterbalance each other or may not be strong enough to influence atherogenesis, and reveals that targeting haematopoietic Ikk α kinase activity alone may not represent a suitable therapeutic approach. Although the overall zero effect on atherosclerosis is surprising at first sight, it has been observed before that deficiency of proteins with an important role in inflammatory signalling and biological processes does not induce

any changes in the size or composition of atherosclerotic lesions, as for example described for BM-deficiency of *Cd40 ligand* [59,60] or *Traf6* [61]. Also, atherosclerosis was not affected in *Ldlr^{-/-}* mice with a BM *p16^{INK4a}*-deficiency [62], despite the fact that p16^{INK4a} is a regulator of macrophage activation and polarization and *p16^{INK4a}*-deficiency reduces LPS-induced NF- κ B activation in BM-derived macrophages [63]. Clearly, it would be interesting to address in the future the role of the IKK α kinase in atherosclerosis in different leukocyte subsets individually and in vascular cells.

Supporting Information

Figure S1 Effect of a bone marrow-specific *Ikk α ^{AA/AA}* knock-in on B- and T-cell populations in bone marrow and secondary lymphoid organs. Shown is flow cytometric analysis of bone marrow, spleen and lymph nodes from *Apoe^{-/-}* mice transplanted with *Ikk α ^{AA/AA}Apoe^{-/-}* or *Ikk α ^{+/+}Apoe^{-/-}* BM and receiving a high-cholesterol diet for 13 weeks. (A) Cd19⁺ B-cell population as percentage of Cd45⁺ leukocytes. (B–C) Cd19⁺ B-cell and Cd3⁺ T-cell populations as percentage of Cd45⁺ leukocytes, and Cd4⁺ and Cd8a⁺ T-cell subsets as percentage of Cd3⁺ T-cells in lymph nodes (B) and spleen (C). All graphs represent the mean \pm SEM (n = 18–19), 2-tailed t-test, ***P<0.001. (DOCX)

Figure S2 Effect of a bone marrow-specific *Ikk α ^{AA/AA}* knock-in on T_{reg}, naive and effector memory T-cells. Shown are representative dot plots of the FACS-based gating strategy of T-cell subpopulations within splenic leukocytes from *Ikk α ^{+/+}Apoe^{-/-}* and *Ikk α ^{AA/AA}Apoe^{-/-}* BM chimeras after 13 weeks of high-cholesterol diet. (A) Within the Cd3⁺ T-cell population, T_{reg} cells were defined as Cd4⁺Cd25⁺Foxp3⁺ cells. (B) Within the Cd3⁺ T-cell population, naive T-cells were defined as Cd44^{low}Cd62L^{high} T-cells and effector memory T-cells as Cd44^{high}Cd62L^{low} T-cells. (A,B) Percentages indicate the % from the Cd3⁺ T-cell population. (DOCX)

Figure S3 Effect of a bone marrow-specific *Ikk α ^{AA/AA}* knock-in on central memory T-cells. Shown is flow cytometric analysis of Cd44^{high}Cd62L^{high} central memory T-cells in spleen and lymph nodes from *Apoe^{-/-}* mice transplanted with *Ikk α ^{AA/AA}Apoe^{-/-}* or *Ikk α ^{+/+}Apoe^{-/-}* BM and receiving a high-cholesterol diet for 13 weeks. Data are represented as percentage of Cd3⁺ T-cells (left) and as percentage of Cd45⁺ leukocytes (right). Graphs represent the mean \pm SEM (n = 18–19), 2-tailed t-test, *P<0.05, **P<0.01, ***P<0.001. (DOCX)

Figure S4 Effect of a bone marrow-specific *Ikk α ^{AA/AA}* knock-in on B- and T-cell populations in a non-atherosclerotic context. Shown is flow cytometric analysis of spleen and lymph nodes from C57BL/6 mice transplanted with *Ikk α ^{AA/AA}* or *Ikk α ^{+/+}* BM. Dead cells were excluded using Sytox Blue. (A) B220⁺ B-cell population as percentage of leukocytes, and the total number of B-cells in spleen and lymph nodes. (B) Cd4⁺ and Cd8a⁺ T-cell subsets as percentage of leukocytes, and as percentage of Cd3⁺ T-cells. (C) Total number of Cd3⁺Cd4⁺ and

Cd3⁺Cd8a⁺ T-cell subsets, and total leukocyte number in spleen and lymph nodes. All graphs represent the mean \pm SEM (n = 5); 2-tailed t-test; *P<0.05, **P<0.01, ***P<0.001. (DOCX)

Figure S5 Effect of a bone marrow-specific *Ikk α ^{AA/AA} knock-in on T_{reg}-cells in a non-atherosclerotic context.* Shown is flow cytometric analysis of T_{reg}-cells in lymph nodes from C57BL/6 mice transplanted with *Ikk α ^{AA/AA}* or *Ikk α ^{+/+}* BM. Dead cells were excluded using Sytox Blue. (A) Cd4⁺Foxp3⁺ T_{reg}-cells as percentage of leukocytes (left), and Cd4⁺Cd25⁺Foxp3⁺ T_{reg}-cells as percentage of Cd4⁺ T-cells (right). (B) Total numbers of Cd4⁺Foxp3⁺ T_{reg}-cells (left), and total numbers of Cd4⁺Cd25⁺Foxp3⁺ T_{reg}-cells. Graphs represent the mean \pm SEM (n = 5), 2-tailed t-test, *P<0.05, **P<0.01, ***P<0.001. (DOCX)

Figure S6 Effect of *Ikk α ^{AA/AA} knock-in on cytokine secretion from BM-derived macrophages.* Shown are cytokine concentrations of Il-10 and Il-12p70 in the supernatants

References

- Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. *Nat Immunol* 12: 204–212.
- Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. *Nat Med* 17: 1410–1422.
- de Winther MP, Kanters E, Kraal G, Hofker MH (2005) Nuclear factor kappaB signaling in atherogenesis. *Arterioscler Thromb Vasc Biol* 25: 904–914.
- Oeckinghaus A, Hayden MS, Ghosh S (2011) Crosstalk in NF-kappaB signaling pathways. *Nat Immunol* 12: 695–708.
- Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. *Oncogene* 18: 6853–6866.
- Chiba T, Kondo Y, Shinozaki S, Kaneko E, Ishigami A, et al. (2006) A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. *J Atheroscler Thromb* 13: 308–313.
- Gareus R, Kotsaki E, Xanthouleas S, van der Made I, Gijbels MJ, et al. (2008) Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. *Cell Metab* 8: 372–383.
- Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA (2001) Possible new role for NF-kappaB in the resolution of inflammation. *Nat Med* 7: 1291–1297.
- Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, et al. (2007) NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. *Cell* 130: 918–931.
- Fong CH, Bebien M, Didierlaurent A, Nebauer R, Hussell T, et al. (2008) An antiinflammatory role for IKKbeta through the inhibition of “classical” macrophage activation. *J Exp Med* 205: 1269–1276.
- Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, et al. (2003) Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. *J Clin Invest* 112: 1176–1185.
- Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, et al. (1999) Limb and skin abnormalities in mice lacking IKKalpha. *Science* 284: 313–316.
- Li ZW, Chu W, Hu Y, Delhase M, Deerincq T, et al. (1999) The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. *J Exp Med* 189: 1839–1845.
- Chariot A (2009) The NF-kappaB-independent functions of IKK subunits in immunity and cancer. *Trends Cell Biol* 19: 404–413.
- Senfiteben U, Cao Y, Xiao G, Greten FR, Krahn G, et al. (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. *Science* 293: 1495–1499.
- Perry HM, Bender TP, McNamara CA (2012) B cell subsets in atherosclerosis. *Front Immunol* 3: 373.
- Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, et al. (2003) A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. *Nature* 423: 659–663.
- Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB (2003) Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. *Nature* 423: 655–659.
- Lawrence T, Bebien M, Liu GY, Nizet V, Karin M (2005) IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. *Nature* 434: 1138–1143.
- Liu B, Yang Y, Chernishov F, Loo RR, Jang H, et al. (2007) Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. *Cell* 129: 903–914.
- Shembade N, Pujari R, Harhaj NS, Abbott DW, Harhaj EW (2011) The kinase IKKalpha inhibits activation of the transcription factor NF-kappaB by phosphorylating the regulatory molecule TAX1BP1. *Nat Immunol* 12: 834–843.
- Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, et al. (2001) IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. *Cell* 107: 763–775.
- Parini P, Johansson L, Broijersens A, Angelin B, Rudling M (2006) Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. *Eur J Clin Invest* 36: 98–104.
- Davies J, Gordon S (2005) Isolation and Culture of Murine Macrophages. From: *Methods in Molecular Biology*; Miller DHA, editor: Humana Press Inc., Totowa, Nj.
- Marim FM, Silveira TN, Lima DS Jr, Zamboni DS (2010) A method for generation of bone marrow-derived macrophages from cryopreserved mouse bone marrow cells. *PLoS One* 5: e15263.
- Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, et al. (2006) Natural regulatory T cells control the development of atherosclerosis in mice. *Nat Med* 12: 178–180.
- Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu Rev Immunol* 22: 745–763.
- Kaisho T, Takeda K, Tsujimura T, Kawai T, Nomura F, et al. (2001) IkappaB kinase alpha is essential for mature B cell development and function. *J Exp Med* 193: 417–426.
- Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, et al. (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. *Science* 293: 2111–2114.
- Balkhi MY, Willette-Brown J, Zhu F, Chen Z, Liu S, et al. (2012) IKKalpha-mediated signaling circuitry regulates early B lymphopoiesis during hematopoiesis. *Blood* 119: 5467–5477.
- Mancino A, Habbedine M, Johnson E, Luron L, Bebien M, et al. (2013) I kappa B kinase alpha (IKKalpha) activity is required for functional maturation of dendritic cells and acquired immunity to infection. *Embo J* 32: 816–828.
- Hacker H, Chi L, Reh JE, Redecke V (2012) NIK prevents the development of hyper eosinophilic syndrome-like disease in mice independent of IKKalpha activation. *J Immunol* 188: 4602–4610.
- Matsushima A, Kaisho T, Rennert PD, Nakano H, Kurosawa K, et al. (2001) Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lipopolysaccharide beta receptor, but not through tumor necrosis factor receptor I. *J Exp Med* 193: 631–636.
- Fagarasan S, Shinkura R, Kamata T, Nogaki F, Ikuta K, et al. (2000) Alymphoplasia (aly)-type nuclear factor kappaB-inducing kinase (NIK) causes defects in secondary lymphoid tissue chemokine receptor signaling and homing of peritoneal cells to the gut-associated lymphatic tissue system. *J Exp Med* 191: 1477–1486.
- Xiao G, Harhaj EW, Sun SC (2001) NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. *Mol Cell* 7: 401–409.
- Hofmann J, Mair F, Greter M, Schmidt-Supprian M, Becher B (2011) NIK signaling in dendritic cells but not in T cells is required for the development of effector T cells and cell-mediated immune responses. *J Exp Med* 208: 1917–1929.
- Tamura C, Nakazawa M, Kasahara M, Hotta C, Yoshinari M, et al. (2006) Impaired function of dendritic cells in alymphoplasia (aly/aly) mice for expansion of CD25+CD4+ regulatory T cells. *Autoimmunity* 39: 445–453.
- Murray SE (2013) Cell-intrinsic role for NF-kappa B-inducing kinase in peripheral maintenance but not thymic development of Foxp3+ regulatory T cells in mice. *PLoS One* 8: e76216.

Acknowledgments

We are grateful to Prof. A. Schober and Prof. N. Marx for their support. Furthermore, we thank Roya Soltan, Melanie Garbe, Stephanie Elbin and Inja Ilic for excellent technical assistance.

Author Contributions

Conceived and designed the experiments: MPJdW TL JB AZ CW HN. Performed the experiments: PVT MJG MH CC YA WT BZ YD MD LP SS RRR HN. Analyzed the data: PVT MJG MH CC WT BZ RRR HN. Wrote the paper: PVT CW HN.

39. Kajiura F, Sun S, Nomura T, Izumi K, Ueno T, et al. (2004) NF-kappa B-inducing kinase establishes self-tolerance in a thymic stroma-dependent manner. *J Immunol* 172: 2067–2075.
40. Tas SW, Vervoordeldonk MJ, Hajji N, Schuitemaker JH, van der Sluijs KF, et al. (2007) Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. *Blood* 110: 1540–1549.
41. Puccetti P, Grohmann U (2007) IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. *Nat Rev Immunol* 7: 817–823.
42. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR (2008) The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. *J Immunol* 181: 5396–5404.
43. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, et al. (2011) Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. *Nat Immunol* 12: 870–878.
44. Proietto AI, van Dommelen S, Zhou P, Rizzitelli A, D'Amico A, et al. (2008) Dendritic cells in the thymus contribute to T-regulatory cell induction. *Proc Natl Acad Sci U S A* 105: 19869–19874.
45. Klingenberg R, Gerdes N, Badeau RM, Gistera A, Strothoff D, et al. (2013) Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. *J Clin Invest* 123: 1323–1334.
46. Major AS, Fazio S, Linton MF (2002) B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. *Arterioscler Thromb Vasc Biol* 22: 1892–1898.
47. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M (2004) TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. *J Immunol* 173: 2245–2252.
48. Kyaw T, Tay C, Hossini H, Kanellakis P, Gadowski T, et al. (2012) Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. *PLoS One* 7: e29371.
49. Sage AP, Tsiantoulas D, Baker L, Harrison J, Masters L, et al. (2012) BAFF receptor deficiency reduces the development of atherosclerosis in mice—brief report. *Arterioscler Thromb Vasc Biol* 32: 1573–1576.
50. Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, et al. (2012) Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. *J Am Heart Assoc* 1: 27–41.
51. Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, et al. (2010) Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. *J Exp Med* 207: 391–404.
52. Tabas I (2010) Macrophage death and defective inflammation resolution in atherosclerosis. *Nat Rev Immunol* 10: 36–46.
53. Baitsch D, Bock HH, Engel T, Telgmann R, Muller-Tidow C, et al. (2011) Apolipoprotein E induces antiinflammatory phenotype in macrophages. *Arterioscler Thromb Vasc Biol* 31: 1160–1168.
54. Brand K, Page S, Rogler G, Bartsch A, Brandl R, et al. (1996) Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. *J Clin Invest* 97: 1715–1722.
55. Wilson SH, Best PJ, Edwards WD, Holmes DR Jr, Carlson PJ, et al. (2002) Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. *Atherosclerosis* 160: 147–153.
56. Monaco C, Andreaskos E, Kiriakidis S, Mauri C, Bicknell C, et al. (2004) Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. *Proc Natl Acad Sci U S A* 101: 5634–5639.
57. Kanters E, Gijbels MJ, van der Made I, Vergouwe MN, Heeringa P, et al. (2004) Hematopoietic NF-kappaB1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype. *Blood* 103: 934–940.
58. Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, et al. (2010) MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. *Nat Immunol* 11: 799–805.
59. Smook ML, Heeringa P, Damoiseaux JG, Daemen MJ, de Winther MP, et al. (2005) Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. *Atherosclerosis* 183: 275–282.
60. Bavendiek U, Zirikli A, LaClair S, MacFarlane L, Libby P, et al. (2005) Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. *Arterioscler Thromb Vasc Biol* 25: 1244–1249.
61. Stachon P, Missiou A, Walter C, Varo N, Colberg C, et al. (2010) Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans. *PLoS One* 5: e11589.
62. Wouters K, Cudejko C, Gijbels MJ, Fuentes L, Bantubungi K, et al. (2012) Bone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis development. *PLoS One* 7: e32440.
63. Cudejko C, Wouters K, Fuentes L, Hannou SA, Paquet C, et al. (2011) p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. *Blood* 118: 2556–2566.